MY208220A - Fc-optimized anti-cd25 for tumour specific cell depletion - Google Patents
Fc-optimized anti-cd25 for tumour specific cell depletionInfo
- Publication number
- MY208220A MY208220A MYPI2019005313A MYPI2019005313A MY208220A MY 208220 A MY208220 A MY 208220A MY PI2019005313 A MYPI2019005313 A MY PI2019005313A MY PI2019005313 A MYPI2019005313 A MY PI2019005313A MY 208220 A MY208220 A MY 208220A
- Authority
- MY
- Malaysia
- Prior art keywords
- specific cell
- cell depletion
- tumour specific
- optimized anti
- optimized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17161717 | 2017-03-17 | ||
| GBGB1710879.6A GB201710879D0 (en) | 2017-07-06 | 2017-07-06 | Methods and compounds for tumour-specific cell depletion |
| GBGB1714429.6A GB201714429D0 (en) | 2017-09-07 | 2017-09-07 | Compounds and methods for tumour-specific cell depletion |
| PCT/EP2018/056312 WO2018167104A1 (en) | 2017-03-17 | 2018-03-13 | Fc-optimized anti-cd25 for tumour specific cell depletion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY208220A true MY208220A (en) | 2025-04-24 |
Family
ID=61655786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2019005313A MY208220A (en) | 2017-03-17 | 2018-03-13 | Fc-optimized anti-cd25 for tumour specific cell depletion |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US11879014B2 (enExample) |
| EP (1) | EP3596123B1 (enExample) |
| JP (2) | JP2020514363A (enExample) |
| KR (1) | KR20190130137A (enExample) |
| CN (1) | CN110869388B (enExample) |
| AU (1) | AU2018233976B2 (enExample) |
| BR (1) | BR112019017017A2 (enExample) |
| CA (1) | CA3056506A1 (enExample) |
| CL (1) | CL2019002624A1 (enExample) |
| CR (1) | CR20190477A (enExample) |
| DK (1) | DK3596123T3 (enExample) |
| ES (1) | ES2975063T3 (enExample) |
| FI (1) | FI3596123T3 (enExample) |
| HR (1) | HRP20240469T1 (enExample) |
| HU (1) | HUE065999T2 (enExample) |
| IL (1) | IL269081A (enExample) |
| LT (1) | LT3596123T (enExample) |
| MX (1) | MX2019010974A (enExample) |
| MY (1) | MY208220A (enExample) |
| NZ (1) | NZ756984A (enExample) |
| PE (1) | PE20191812A1 (enExample) |
| PL (1) | PL3596123T3 (enExample) |
| RS (1) | RS65351B1 (enExample) |
| SG (1) | SG11201908578YA (enExample) |
| SI (1) | SI3596123T1 (enExample) |
| WO (1) | WO2018167104A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017011592A1 (en) | 2015-07-13 | 2017-01-19 | Modular Genetics, Inc. | Generation of acyl alcohols |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| CR20200466A (es) * | 2018-03-13 | 2020-11-11 | Tusk Therapeutics Ltd | Agentes anticuerpos anti-cd25 |
| JP7619941B2 (ja) * | 2018-11-14 | 2025-01-22 | アイバイオ， インク． | Ｃｄ２５抗体 |
| JP7695881B2 (ja) * | 2018-11-14 | 2025-06-19 | アイバイオ， インク． | 操作されたｃｄ２５ポリペプチドおよびその使用 |
| US20220251232A1 (en) * | 2019-05-20 | 2022-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel anti-cd25 antibodies |
| ES3037019T3 (en) * | 2019-06-10 | 2025-09-26 | Shandong Boan Biotechnology Co Ltd | Anti-cd25 antibody and application thereof |
| BR112022020521A2 (pt) | 2020-04-10 | 2023-03-07 | Rakuten Medical Inc | Compostos de corante ftalocianina, conjugados e métodos de uso dos mesmos |
| TW202144429A (zh) | 2020-05-14 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｃｄ２５抗體、其抗原結合片段及其醫藥用途 |
| US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
| WO2022106663A1 (en) * | 2020-11-20 | 2022-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd25 antibodies |
| EP4247497A1 (en) * | 2020-11-20 | 2023-09-27 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Anti-cd25 antibodies |
| US20240018248A1 (en) | 2020-12-02 | 2024-01-18 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| EP4288100A1 (en) * | 2021-02-02 | 2023-12-13 | Rakuten Medical, Inc. | Methods for local and systemic treatment of cancers, tumors and tumor cells |
| CA3209636A1 (en) | 2021-03-01 | 2022-09-09 | F. Hoffmann-La Roche Ag | Novel biomarkers and uses thereof |
| CN117916266A (zh) | 2021-09-02 | 2024-04-19 | 弗哈夫曼拉罗切有限公司 | 用于治疗aml的抗体 |
| CN119095621A (zh) | 2022-04-26 | 2024-12-06 | 弗哈夫曼拉罗切有限公司 | 用于治疗癌症的包括Fas轴拮抗剂和T-reg细胞消耗剂拮抗剂的联合疗法 |
| CN115181182B (zh) * | 2022-06-13 | 2024-03-29 | 南京融捷康生物科技有限公司 | 一种人源化的抗cd25的单域抗体及其应用 |
| WO2024006965A1 (en) * | 2022-06-30 | 2024-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cd25-specific antibodies and uses thereof |
| WO2024006961A1 (en) | 2022-07-01 | 2024-01-04 | Neoleukin Therapeutics, Inc. | Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| CN118240080A (zh) * | 2022-12-22 | 2024-06-25 | 深圳市福元生物科技有限公司 | 一种cd25单域抗体、人源化抗体、及制备方法 |
| EP4662238A1 (en) | 2023-02-06 | 2025-12-17 | F. Hoffmann-La Roche AG | Combination therapy and uses thereof |
| CN116087499B (zh) * | 2023-02-20 | 2023-10-31 | 深圳裕康医学检验实验室 | 一种癌样本的染色方法及试剂盒 |
| CN120314588B (zh) * | 2025-05-21 | 2025-10-17 | 成都蓉生药业有限责任公司 | 一种人免疫球蛋白抗体依赖性细胞介导的吞噬作用生物学活性的检测方法和检测试剂盒 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| NZ540555A (en) | 2002-11-15 | 2008-04-30 | Genmab As | Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders |
| WO2004063355A2 (en) | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
| GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| GB0507696D0 (en) | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
| EP2032159B1 (en) | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| CA2656700A1 (en) | 2006-07-06 | 2008-01-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| EP2423231A3 (en) | 2006-08-18 | 2012-05-30 | Novartis AG | PRLR-specific antibody and uses thereof |
| RU2391401C2 (ru) | 2008-02-12 | 2010-06-10 | Общество с ограниченной ответственностью "Лаборатория клеточного мониторинга" | СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ |
| DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| JP5746183B2 (ja) | 2009-09-22 | 2015-07-08 | プロビオゲン アーゲー | 特定のグリカン構造を含有する分子を生成する方法 |
| SG181690A1 (en) * | 2009-12-21 | 2012-07-30 | Regeneron Pharma | Humanized fcy r mice |
| AR079944A1 (es) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
| RU2598711C2 (ru) | 2010-07-22 | 2016-09-27 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Антитело к противоопухолевому антигену и способы применения |
| CA2904532A1 (en) | 2013-03-15 | 2014-09-18 | Abbvie Biotechnology Ltd. | Anti-cd25 antibodies and their uses |
| CA2904527A1 (en) | 2013-03-15 | 2014-09-18 | Abbvie Biotechnology Ltd. | Anti-cd25 antibodies and their uses |
| DK2970486T3 (en) * | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
| GB2526139A (en) | 2014-05-15 | 2015-11-18 | Biolnvent Internat Ab | Medicaments, uses and methods |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| BR112018070636A2 (pt) | 2016-04-07 | 2019-02-05 | Cancer Research Technology Limited | método de tratamento de um sujeito humano que tem câncer, anticorpo, uso de um anticorpo, anticorpo para uso, combinação de um anticorpo, kit para uso no tratamento de câncer, composição farmacêutica, anticorpo biespecífico, método para tratamento de câncer, anticorpo biespecífico para uso e método de depleção de células t reguladoras em um tumor sólido em um sujeito |
| JP2019532996A (ja) | 2016-11-08 | 2019-11-14 | デリニア，インコーポレーテッド | 自己免疫疾患を処置するためのｉｌ−２変異体 |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| MA51992A (fr) | 2018-03-13 | 2021-06-23 | Cancer Research Tech Ltd | Anticorps anti-cd25 pour la déplétion de cellules spécifiques d'une tumeur |
-
2018
- 2018-03-03 US US16/494,962 patent/US11879014B2/en active Active
- 2018-03-13 NZ NZ756984A patent/NZ756984A/en unknown
- 2018-03-13 PE PE2019001847A patent/PE20191812A1/es unknown
- 2018-03-13 MY MYPI2019005313A patent/MY208220A/en unknown
- 2018-03-13 MX MX2019010974A patent/MX2019010974A/es unknown
- 2018-03-13 HR HRP20240469TT patent/HRP20240469T1/hr unknown
- 2018-03-13 RS RS20240376A patent/RS65351B1/sr unknown
- 2018-03-13 WO PCT/EP2018/056312 patent/WO2018167104A1/en not_active Ceased
- 2018-03-13 DK DK18711313.9T patent/DK3596123T3/da active
- 2018-03-13 LT LTEPPCT/EP2018/056312T patent/LT3596123T/lt unknown
- 2018-03-13 AU AU2018233976A patent/AU2018233976B2/en active Active
- 2018-03-13 CR CR20190477A patent/CR20190477A/es unknown
- 2018-03-13 EP EP18711313.9A patent/EP3596123B1/en active Active
- 2018-03-13 FI FIEP18711313.9T patent/FI3596123T3/fi active
- 2018-03-13 PL PL18711313.9T patent/PL3596123T3/pl unknown
- 2018-03-13 BR BR112019017017A patent/BR112019017017A2/pt unknown
- 2018-03-13 JP JP2019550705A patent/JP2020514363A/ja active Pending
- 2018-03-13 SI SI201831085T patent/SI3596123T1/sl unknown
- 2018-03-13 KR KR1020197030283A patent/KR20190130137A/ko not_active Ceased
- 2018-03-13 HU HUE18711313A patent/HUE065999T2/hu unknown
- 2018-03-13 CA CA3056506A patent/CA3056506A1/en active Pending
- 2018-03-13 SG SG11201908578Y patent/SG11201908578YA/en unknown
- 2018-03-13 ES ES18711313T patent/ES2975063T3/es active Active
- 2018-03-13 CN CN201880018976.8A patent/CN110869388B/zh active Active
-
2019
- 2019-09-02 IL IL26908119A patent/IL269081A/en unknown
- 2019-09-13 CL CL2019002624A patent/CL2019002624A1/es unknown
-
2024
- 2024-01-25 JP JP2024009215A patent/JP2024050684A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| LT3596123T (lt) | 2024-03-25 |
| PL3596123T3 (pl) | 2024-06-24 |
| US20200010554A1 (en) | 2020-01-09 |
| CR20190477A (es) | 2020-01-07 |
| MX2019010974A (es) | 2020-08-03 |
| SG11201908578YA (en) | 2019-10-30 |
| AU2018233976B2 (en) | 2025-03-20 |
| SI3596123T1 (sl) | 2024-05-31 |
| WO2018167104A1 (en) | 2018-09-20 |
| JP2020514363A (ja) | 2020-05-21 |
| PE20191812A1 (es) | 2019-12-26 |
| FI3596123T3 (fi) | 2024-04-17 |
| EP3596123A1 (en) | 2020-01-22 |
| IL269081A (en) | 2019-11-28 |
| BR112019017017A2 (pt) | 2020-04-14 |
| CA3056506A1 (en) | 2018-09-20 |
| AU2018233976A1 (en) | 2019-10-31 |
| KR20190130137A (ko) | 2019-11-21 |
| HUE065999T2 (hu) | 2024-06-28 |
| JP2024050684A (ja) | 2024-04-10 |
| CL2019002624A1 (es) | 2020-04-03 |
| HRP20240469T1 (hr) | 2024-07-19 |
| DK3596123T3 (da) | 2024-02-26 |
| CN110869388A (zh) | 2020-03-06 |
| EP3596123B1 (en) | 2024-01-10 |
| RS65351B1 (sr) | 2024-04-30 |
| ES2975063T3 (es) | 2024-07-03 |
| NZ756984A (en) | 2025-08-29 |
| US11879014B2 (en) | 2024-01-23 |
| CN110869388B (zh) | 2024-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY208220A (en) | Fc-optimized anti-cd25 for tumour specific cell depletion | |
| PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| MY205760A (en) | Humanized antibodies against c-kit | |
| AU2018265888A1 (en) | Use of anti-B7H3 antibodies for treating cancer in the central nervous system | |
| PH12019501253A1 (en) | Anti-tim-3 antibodies for combination with anti-pd-1 antibodies | |
| PH12019500369A1 (en) | Anti-tim-3 antibodies | |
| MX2023001403A (es) | Neoantigenos y metodos de su uso. | |
| EP4417263A3 (en) | Cd3 binding antibodies | |
| MX2019001471A (es) | Anticuerpos anti-siglec-7 para el tratamiento del cancer. | |
| MX2016004570A (es) | Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer. | |
| MX2017007250A (es) | Celulas t modificadas en receptor de antigeno quimerico dirigo a cs1. | |
| NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
| PH12016501680A1 (en) | Anti-egfrviii antibodies and uses thereof | |
| TW201613648A (en) | Compounds and compositions for immunotherapy | |
| PH12019500643A1 (en) | Antibodies that bind interleukin-2 and uses thereof | |
| MY176517A (en) | Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia | |
| PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
| WO2019234241A8 (en) | ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT | |
| JOP20150008B1 (ar) | أجسام مضادة ل vista وأجزاء منها | |
| EA201990370A1 (ru) | Терапия рака, связанная с crebbp | |
| PH12021550035A1 (en) | Combination therapy | |
| PH12020551453A1 (en) | Anti-cd25 for tumour specific cell depletion | |
| PH12017502011A1 (en) | Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer | |
| MX2020005424A (es) | Composiciones y metodos para terapia contra el cancer. |